he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看离散地址
上一页:预测癫痫患者再入院风险
下一页:小儿脑瘫诊疗的方法_1
- 2022-04-272013年International抗癫痫联合会抗癫痫药使用指南
- 2022-04-26癫痫病抑制的主要病因是什么
- 2022-04-202013年全球性抗癫痫联合会抗癫痫药使用指南
- 2019-04-21绥化市哪家医院治癫痫便宜
- 预测癫痫患者再入院风险
- 三庚酸酯可治疗1型转运体缺陷综合征
- 月经性癫痫患者妊娠期癫痫控制更好
- 北京妇产医院第十届妇科内镜手拉手培训班
- 抗癫痫药物预防新发癫痫:任重而道远
- 综述:癫痫持续状态诊治最新进展
- 癫痫猝死:凶手是谁?
- 副教授赵倩华谈到了认知障碍的早期诊断策略
- 癫痫定位新方法:无框架立体定向脑电图技术
- 癫痫治疗障碍仍难以克服
- 治疗癫痫 治疗癫痫偏方大全
- 癫痫患者手术评估新型工具
- Neurology:颅脑损伤增加了迟发性癫痫的风险,高损伤频率、重伤、老年人尤其是
- 如何使用难治性癫痫持续状态剂?
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 癫痫患者如何克服忘记吃药的问题?
- Circ Ep:左室肥厚高血压患者新发房颤增加SCD风险
- 不注意这些问题,吃多少药都没用!
- 2015第31届国际癫痫大会(IEC)
- 2015 神经系统疾病诊疗进展
- 心理百科:春节期间小心疾病
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 癫痫需要如何诊断?
- 月经期间要注意 有些药物和食物不能食用
- 女性腹痛不容轻视,小心是妇科疾病!学四招保护小肚子
- 脑梗死的症状是什么有这些前兆要谨慎
- UCB的Vimpat癫痫新适应症在美国获批
- 烧口综合征注意事项!
- 睡眠要好怎么办 睡眠要好竟然会致命(2)
- 怎么清领癫痫病最有效啊
- 围剿癫痫在中国:20年征程,从临床走向公卫战略
- 脑瘤发生调控机制研究获新发现
- 癫痫病的病征有哪些
- 女同性恋体检 定期体检摆脱妇科亚健康
- 治疗癫痫病比较好的原理有哪些
- 答疑癫痫100问第四期:哪些后天因素最容易造成了癫痫?
- 卫材在法国推出新一代抗癫痫泻药Fycompa
- 带鱼寿司 带鱼不一样的米饭
- 于今癫痫病哪里好效果好吗
- 【高考要点】考生癫痫突发怎么办?如何避免?